Tiziana Life Sciences PLC appointed Dr. Kunwar Shailubhai (Shailu) as Chief Executive Officer and Chief Scientific Officer with immediate effect. Shailu was previously a Non-Executive Director at the company. He takes the reins of the company at a significant time for Tiziana Life Sciences, which is the only company in the world developing an orally administered fully human anti-CD3 mAb (foralumab) as a drug candidate to manage NASH, a liver disease that affects millions of people worldwide, for which there is currently no treatment.

The timing of his appointment is noteworthy as Tiziana prepares to proceed with Phase II of its trials to develop foralumab as a treatment for NASH. Shailu has extensive experience within the sector, drawing on 30 years of experience in research and development of drug candidates for treatment of gastrointestinal disorders, inflammatory diseases and cancers. His appointment follows many years working at Synergy Pharmaceuticals Inc., which he co-founded and where he served as chief scientific officer since 2008.